Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has announced additional positive data from its Phase 2 clinical trial of PV-10 for metastatic melanoma. The data, on changes in visceral and nodal metastases following chemoablation of cutaneous melanoma lesions with PV-10, was presented by Dr.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/pvct/43978/
The controversy surrounding tanning continues to mount. More and more young women are being diagnosed with melanoma and the incidence of painful sunburns from tanning beds is becoming more frequent. These health hazards, coupled with the recent exposé of New Jersey “tanning mom,” have led to a recent backlash against the dark bronze look.
May is Melanoma Awareness month, and now more than ever, people across the country, from teens to fashion and beauty icons, are taking a stand against the deep suntan and looking for ways to get a gorgeous glow without tanning. Jergens® offers the ultimate solution to get a healthy-looking glow and keep your skin safe with Natural Glow & Protect Daily Moisturizer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56364-jergens-natural-glow-and-protect-daily-moisturizer-ban-the-tan
In recognition of Melanoma Monday® and National Melanoma/Skin Cancer Detection & Prevention MonthTM, MELA Sciences, Inc. (NASDAQ: MELA) visited the NASDAQ MarketSite in Times Square today to ring the Opening Bell and sponsor free skin cancer checks.
One American dies every hour from melanoma, the most deadly skin cancer. MELA Sciences, Inc. is the pioneer company behind MelaFind®, the first and only FDA-approved diagnostic tool that helps dermatologists detect melanoma at its most curable stage. MelaFind® was approved by the U.S. Food & Drug Administration (FDA) in Fall 2011, and since then has strategically rolled out the technology to dermatology practices across the country.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61584-mela-sciences-rings-opening-bell-awareness-melanoma-detection-prevention
Millions of families will head to the beach this Memorial Day weekend, many without adequate sun protection. As part of a national effort to reduce the incidence of skin cancer, Neutrogena® is kicking off the 2016 Choose Skin Health® Campaign with a video featuring Brand Ambassador Kristen Bell asking moms everywhere to get real with their kids about the importance of sunscreen—and a pledge to donate $1 for every video share to the non-profit Children’s Melanoma Prevention Foundation.*
Bell’s video acknowledging the challenges moms face tackling serious topics with their children is frank and funny—but skin health is no laughing matter. The fact that only 39% of women and 14% of men use sunscreen regularly is a health issue of national importance when you consider that just one to two severe sunburns can increase lifetime risk of developing melanoma by 40 percent.
The Neutrogena® Choose Skin Health® Campaign was created to change the future of skin health and reduce the risk of skin cancer through education, empowerment, and early detection. This year the brand is developing in-school sun safety programs with the potential to reach 1.6 million students annually with a sun safe behavior curriculum, sponsoring 13,000 free skin cancer screenings annually with charitable partners, and working toward a goal of donating $35 million worth of sunscreen to families in need by the end of 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7847951-neutrogena-choose-skin-health/
Currently melanoma is the deadliest form of skin cancer and one of the most common cancers in women under 40 years old in the United States. The first line of defense in helping to reduce the risk of developing melanoma is by wearing broad spectrum UVA and UVB SPF protection. L’Oréal Paris, a leading global beauty brand, and Melanoma Research Alliance (MRA), the leading private funder of melanoma research, announced today the launch of It’s THAT Worth It To Me. This social media campaign encourages women to donate 15 social media seconds by sharing why SPF protection or using sunless tanner is worth it to protect their skin, their beauty and their life. For every social share, L’Oréal Paris will donate $1 to MRA to fund the L’Oréal Paris - MRA Team Science Award Research Grant, up to $250,000 in 2015.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7459051-l-oreal-paris-mra-it-s-that-worth-it/
If diagnosed early enough 90% of melanoma cases can be treated effectively. An exclusive study carried out by Ipsos for La Roche-Posay in 23 countries across all continents looks into the different attitudes to the sun and general knowledge of the risks associated with exposure. A massive 88% of those questioned are aware of the risks of developing skin cancer when exposed without protection to the sun. However, just 1 in 2 of those questioned have ever consulted a dermatologist for a mole screening and 1 in 4 of them have never even checked their own moles on their body.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7438251-la-roche-posay-become-skin-checker/
In recognition of Men’s Health Awareness Month and the start of summer, the American Academy of Dermatology (Academy) has released findings from a new survey, which found that more than 90% of American men know something about skin cancer, but only six in 10 (61%) know how to detect signs on their skin, and even fewer actually visit a doctor for annual skin cancer screenings (18%). These shortcomings were more apparent in younger men (18-34), who were also significantly less likely to believe that they are at risk for skin cancer than men over 35 (31% vs. 42%), and are more likely to protect their skin for cosmetic reasons than they are for health reasons (32% vs. 20%).
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7074231-american-academy-of-dermatology-spot-me-skin-cancer-awareness/
Federally funded research continues to spur progress against cancer; however, accelerating the pace of progress will require robust, sustained, and predictable annual funding increases for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Food and Drug Administration (FDA). Additionally, strong financial support for the National Cancer Moonshot Initiative is required, according to the sixth annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
One of the most exciting new approaches to cancer treatment is cancer immunotherapy. As detailed in the report, the utility of immunotherapy is expanding rapidly. For example, on Aug. 1, 2015, one class of immunotherapeutics, checkpoint inhibitors, was initially approved for just two types of cancer—melanoma and lung cancer. As of Sept. 1, 2016, checkpoint inhibitors have been approved for treating six types of cancer—bladder cancer, head and neck cancer, Hodgkin lymphoma, kidney cancer, lung cancer, and melanoma.
To view the multimedia release go to:
http://www.multivu.com/players/English/7911951-aacr-2016-cancer-progress-report/
